Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche moves Taspoglutide into phase III trials

Roche moves Taspoglutide into phase III trials

10th June 2008

Roche has announced that following positive phase II results for taspoglutide, the compound has been moved into phase III clinical trials.

The compound is the first once-weekly human glucagon-like peptide-1 (GLP-1) for the treatment of diabetes from Roche and Ipsen.

Results for the drug were reported at the congress of the American Diabetes Association, with the compound found to be efficacious and generally well-tolerated in type 2 diabetes patients, with significant glucose control improvements and weight loss seen after eight weeks.

The phase III clinical programme for taspoglutide is expected to start in the second half of this year.

Professor Michael Nauck, head of the Diabeteszentrum Bad Lauterberg, Germany, said: “These data show that taspoglutide is a promising and highly efficacious once weekly treatment for obese patients with type 2 diabetes mellitus no longer controlled on oral antidiabetic medications.”

He added that drug-induced weight loss is especially beneficial for these patients and added that he awaited the publication of phase III results with interest.

Last month, Roche announced the results of a survey suggesting that 94 per cent of patients with type 2 diabetes had not attended any courses to support the management of their condition.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.